- Home
- GAIN vs ALLO Comparison
GAIN vs ALLO Comparison
Compare GAIN & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAIN | ALLO |
|---|---|---|
| Founded | 2005 | 2017 |
| Country | United States | United States |
| Employees | 70 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.5M | 738.4M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | GAIN | ALLO |
|---|---|---|
| Price | $15.91 | $2.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 15 |
| Target Price | ★ $14.75 | $8.35 |
| AVG Volume (30 Days) | 420.2K | ★ 6.2M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.19% | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.07 | N/A |
| Revenue Next Year | $7.32 | $142,416.42 |
| P/E Ratio | $4.38 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.14 | $0.99 |
| 52 Week High | $17.14 | $4.46 |
Technical Indicators
Market Signals| Indicator | GAIN | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 47.27 | 41.17 |
| Support Level | $15.78 | $1.85 |
| Resistance Level | $17.04 | $2.71 |
| Average True Range (ATR) | 0.63 | 0.14 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 51.29 | 28.18 |
Price Performance
Historical ComparisonAbout GAIN Gladstone Investment Corporation Business Development Company
Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S. and to achieve and grow current income by investing in debt securities of established businesses; provide the stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).